Medtech partnership improving stroke outcomes
A strategic partnership between two health tech firms is revolutionising medical care for stroke patients. Visionable, a virtual healthcare model and Brainomix, an AI powered medtech platform are transforming how treatment is delivered.
By utilising the healthtech, medical practitioners are saving time, reducing workload, and improving outcomes, assisting the drive toward tech integration and adding efficiency for better patient care.
Oxford spin out Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke, lung fibrosis, and cancer.
The Brainomix e-Stroke platform, provides clinicians with the most comprehensive stroke imaging solution, driving faster treatment times and improving functional independence for patients.
While Visionable’s digital healthcare collaboration platform allows for use across the care pathway. Connecting front-line responders and members of public on scene to remote specialist clinicians and throughout the care delivery journey. The Lamberhurst, Kent based healthtech firm connects every stage of the treatment journey from hospital treatment, including virtual consultations and multidisciplinary team (MDT) meetings to at-home care.
The partnership has been pioneered by the stroke team at Ipswich Hospital in Suffolk. Patients and staff have already benefitted from faster delivery of care, superior performance metrics, and, most importantly, improved patient outcomes.
The strategic partnership aims to tackle “bottlenecks” along the time-sensitive stroke care pathway.
Riaz Rahman, VP Healthcare Global at Brainomix, added: “Our joint approach will tackle head on many of the known systems bottlenecks where multiple stroke centres are involved in a highly time sensitive pathway.”
Read more - AND Digital Survey reveals a lack of digital skills could be halting Reading business growth
Rob Hughes, Chief Commercial Officer at Visionable, said: “Technology must make life easier for clinicians and improve treatment for patients; Brainomix and Visionable are delivering value in both areas. Combined, our complementary solutions have resulted in quicker delivery of care, instant access to rich data and improved patient outcomes – all while boosting job satisfaction for clinicians.
"The success so far is exciting, and we look forward to the growing impact our partnership will have on the quality of care for stroke patients.”
Lynda Sibson, Telemedicine Manager, East of England Stroke Telemedicine Partnership, spoke to the value that Visionable and Brainomix add to healthcare: “Both systems are easy and intuitive to operate, and highly complementary, ensuring timely sharing of clinical and radiological information that ultimately enables faster patient transfers.
"The companies are true partners, easy to work with and highly responsive. We have also found that the technologies are affording our clinicians more flexibility and an improved work-life balance – not something to be underestimated!”
Dr Sajid Alam, Stroke Consultant at Ipswich Hospital, said: “As a district general hospital, we don’t have ready access to dedicated neuroradiologists to interpret every stroke scan. Having the AI software gives us more confidence when interpreting each scan – particularly the CTA’s, where we look for a large vessel occlusion (LVO), a key indicator of patient eligibility for mechanical thrombectomy.”
Patients admitted to Ipswich Hospital who are eligible for mechanical thrombectomy are transferred to the Royal London Hospital (RLH), a comprehensive stroke centre in Whitechapel that serves as a supraregional thrombectomy hub for Ipswich and a number of other stroke units across the Southeast of England.
Dr Alam added: “In stroke, time is critical. Using e-Stroke saves precious minutes, as the scans are immediately available for viewing on the Brainomix web portal. With RLH also using e-Stroke, we can communicate instantly, share images and make transfer decisions without delay.”
Read more - Seloxium advised by Pennington Manches Cooper on spin-out from Oxford Uni
